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Conclusion: RT remains an important modality in the treatment of 
NHL.  
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Background: Cure rates of patients with lymphoma have improved 
significantly over the last decades because of improved diagnostics, 
chemo(immuno)therapy and radiotherapy. There is, however, a large 
variety of late effects following treatment for lymphoma including 
decreased fertility, hormonal disturbances, pulmonary toxicity, soft 
tissue damage, second malignancies and cardiovascular diseases 
leading to considerable morbidity and excess mortality. The long-term 
burden of lymphoma treatment is determined by a combination of all 
late effects. Since (non) Hodgkin lymphoma ((N)HL) frequently occurs 
at relatively young ages, survivors are subject to the full spectrum of 
early and late side effects of therapy. Over time knowledge and 
awareness of late effects following cancer treatment have increased 
and treatment policies have been adapted accordingly. 
Improvement of treatment: Several randomized clinical trials have 
been performed to determine the role of radiation in lymphoma 
patientsespecially in HL patients. Radiation indication, target volume 
and dose have been subject of study. Since many important long-term 
complications (like second malignancies and cardiovascular toxicity) 
are related to radiation dose and volume, reduction of these 
treatment parameters are expected to ameliorate long-term toxicity 
(1,2). 
Reducing volume 
Over the last decades radiation volumes in lymphoma patients have 
changed considerably because of better knowledge in the spread of 
the disease through improved diagnostic possibilities and improved 
systemic treatments. 
In HL patients for instance radiation field-sizes have been reduced 
from subtotal-nodal or extended field to involved field or, more 
recently, involved site or involved node leading to smaller volumes of 
normal tissues exposed to significantly lower radiation doses. A word 
of caution, however: involved node radiotherapy should not be 
applied strictly when optimal pre-chemotherapy imaging is not 
available to the radiation oncologist. In this situation more generous 
margins should be used including the whole “site” where the 
lymphoma was located before chemotherapy. 
Furthermore, in early stage gastric lymphoma patients, total 
abdominal irradiation has been replaced by radiotherapy limited to 
the stomach and the surrounding lymph nodes using modern radiation 
techniques in selected patients only.  
Reducing dose 
For both HL and many subtypes of NHL systemic treatment options 
have improved significantly. These improvements have led to the 
possibility to reduce both radiation dose and volume while 
maintaining similar treatment outcomes (3). In the past generally 
doses up to 40-45 Gy in fractions of 2 Gy were used. Nowadays 
radiation doses in curative setting usually vary from 20 to 30 Gy and 
sometimes 36 Gy in fractions of 2 Gy. 
Technical improvements 
Deep inspiration breath hold 
In selected patients withmediastinal disease the use of deep 
inspiration breath hold and intensity modulated radiation therapy is 
expected to decrease exposure of the coronary arteries, heart, and 
lungs especially when the target volume is located in the upper part 
of the mediastinum (4).  
Proton therapy 
Another emerging technology is proton therapy. Proton therapy is 
associated with a substantial reduction in radiation dose to critical 
organs, such as the heart and lungs, and therefore has the potential to 
improve not only the therapeutic ratio, but also both event-free and 
overall survival.  
Conclusions 
Patient tailored radiotherapy inlymphoma patients using lower doses, 
smaller and better-defined radiation volumes than in the past, based 
on modern imaging and using conformal radiotherapy are expected to 
lead to an improved therapeutic ratio and decreased late effects. 
Further improvements are expected with the introduction of even 
more modern radiation techniques like deep inspirational breath hold. 
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Hypoxia is a cancer hallmark impacting tumor progression and 
treatment. From a biological standpoint, it promotes (i) a glycolytic 
switch formally corresponding to uncoupling glycolysis from oxidative 
phosphorylation and accelerating the glycolytic flux in order to fulfill 
the energetic and biosynthetic needs of cancer cells, (ii) an 
angiogenic switch, and (iii) a metastatic switch. From a therapeutic 
standpoint, hypoxia provides radioresistance notably because oxygen 
is molecularly involved in the stabilization of radiation-induced DNA 
damage. Among several interventions intended to improve oxygen 
availability to radiosensitize tumors, mathematical models indicate 
that those targeting tumor cell metabolism would be particularly 
efficient. Indeed, even a moderate inhibition of tumor cell respiration 
is predicted to significantly increase tumor oxygenation. 
Switching to a glycolytic metabolism is associated with the abundant 
release of lactate, the level of which positively correlates with tumor 
aggressiveness in patients. Although it was often considered as a mere 
glycolytic end-product, our work over the last 5 years showed that 
lactate is a direct tumor growth-promoting factor influencing tumor 
metabolism and angiogenesis. We first evidenced that lactate is a 
metabolic substrate preferred to glucose to fuel the oxidative 
activities of oxygenated tumor cells. This metabolic preference 
supports a metabolic symbiosis in which (i) hypoxic/glycolytic tumor 
cells produce lactate, (ii) oxygenated/oxidative tumor cells consume 
lactate sparing glucose, and (iii), consequently, glucose is made 
optimally available to fuel accelerated glycolysis in the hypoxic tumor 
cell compartment. Tumor-associated fibroblasts may constitute an 
additional source of lactate. We next found that lactate is also a 
signaling agent promoting tumor angiogenesis. Lactate oxidation to 
pyruvate, the LDH reaction, is shared by both metabolic and signaling 
paths. However, although pyruvate can be consumed in the 
mitochondrion to sustain oxidative ATP production, it can also 
competitively inhibit HIF-1 prolylhydroxylases even under normoxia. 
Lactate thereby activates the transcription factors HIF-1 in 
oxygenated tumor and endothelial cells and NF-κB in endothelial cells, 
thus triggering pro-angiogenic VEGF, bFGF and IL-8 signaling. We 
finally found that the metabolic and signaling use of lactate requires 
monocarboxylate transporter 1 (MCT1), a passive lactate-proton 
symporter located at the outer membrane of oxygenated tumor and 
endothelial cells where it facilitates lactate uptake. Targeting MCT1 
pharmacologically or with RNA interference first induced a glycolytic 
switch and, therefore, oxygen sparing in the oxygenated tumor cell 
compartment. It consequently eradicated the hypoxic tumor cell 
compartment by virtue of glucose starvation, whereas the remaining 
MCT1-positive tumor cells could be efficiently treated with X-ray 
radiotherapy as they were fully reoxygenated. MCT1 inhibition also 
blocked lactate signaling and tumor angiogenesis. 
Conclusively, our study shows (i) that lactate is a pleiotropic tumor 
growth-promoting factor, and (ii) that MCT1 inhibitors combine 
antimetabolic, radiosensitizing, and anti-angiogenic antitumor effects 
within a same molecule. A first MCT1 inhibitor, AZD-3965, is currently 
entering into clinical trials in UK. 
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Tumors similar to normal tissues contain extracellular matrix (ECM). 
Through integrin cell surface receptor binding, cells are integrated 
into multicellular structures and eventually tissues and organs. 
Different from normal tissues are the amount and organization of ECM 
in tumors giving rise to increased intratumoral pressure, tumor cell 
invasion, cancer stem cell niche development,and therapy resistance. 
Our understanding of adhesion-mediated tumor cell radio- and 
chemoresistance are still in its infancy. Evidently, integrin signaling 
activates key pro-survival determinants such as focal adhesion kinase, 
Akt, MAPK among many others, while the structural integrin-mediated 
cell-actin connection controls cell morphology including nuclear 
matrix and chromatin organization. Studies in normal cells such as 
fibroblasts or endothelial cells have revealed that all known cell 
functions ranging from cell survival to metabolism are co-regulated by 
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integrins. Particularly for tumor cells its remains critical that therapy 
resistance emerges from mutually and cooperatively interactions 
between integrins and transmembrane growth factor receptors. How 
exactly such interactions are executed and what consequences result 
from them for tumor cell behavior and bypass signaling for therapy 
resistance will be the great challenge to understand in the next years. 
Additional impact on these processes arises from extracellular matrix 
stiffness in tumors, which is commonly observed relative to normal 
tissues. Despite the fact that ECM stiffness essentially contributes to 
tumor progression, it remains unclear what its role is for tumor cell 
resistance to standard radio(chemo)therapy. What our current view on 
the above mentioned aspects of tumor biology and therapy resistance 
is will be presented. 
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Hypoxia is a common feature of tumors and an important contributor 
to malignancy and treatment resistance. We and others have shown 
that a lysosomal degradation pathway, autophagy, which enables cells 
to recycle and redirect nutrients to adapt to metabolic stresses, is 
required for the survival of hypoxic cells. Consequently, autophagy 
inhibition sensitized tumors to irradiation as determined by tumor 
growth delay experiments.   
Our research focuses on unraveling the molecular mechanisms that 
are required for the activation of autophagy during hypoxia and to 
exploit these for therapeutic purposes. During this presentation, I will 
describe some of our recent findings and how we think that we can 
use autophagy targeting to improve tumor treatment. For example, 
we identified a radioresistant subset of glioblastoma that, when 
metabolically challenged, is highly dependent on autophagy for 
survival.  Its dependency on autophagy provides a novel opportunity to 
delay recurrence of the tumors after treatment.  
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Tumor hypoxia is associated with aggressive disease and poor clinical 
outcome in many types of cancer. This is due in large part to the 
ability of hypoxia to influence important signalling pathways that 
augment metabolism, angiogenesis, genetic instability, and 
metastasis. Recent data suggests that hypoxia may also promote 
stemness in normal stem cell microenvironments, and in the oxygen 
deprived microenvironments of some solid tumors. We have 
discovered a novel potential mechanism that may underlie these 
observations. We found that hypoxia causes a rapid loss of the enzyme 
DICER, an essential component in the miRNA biogenesis pathway. This 
occurs through an epigenetic mechanism that results in transcriptional 
silencing of the DICER1 gene. Loss of DICER during hypoxia or 
following genetic knockdown results in a defect in the creation of 
mature and functional miRNA, and a corresponding increase in miRNA 
precursor forms. However, loss of DICER has a differential effect on 
individual miRNAs and resulted in a particular loss of members of the 
miR200 family. Loss of mIR200 during hypoxia or following DICER1 
knockdown results in derepression of its target ZEB1 and induces an 
epithelial-mesenchymal transition (EMT) characterized by an altered 
cell morphology, loss of E-cadherin, and acquistion of N-cadherin and 
vimentin. In human mammary epithelial cells transformed with 
dominant oncogenes, exposure to hypoxia or knockdown of DICER1 
induces EMT and acquisition of stem cell properties including 
increased sphere formation, and expression of the cell surface 
markers CD24low,CD44high which have been shown to enrich in tumor 
initiating cells.  Importantly, both EMT and acquisition of stem cell 
properties are prevented during hypoxia by overexpression of 
mIR200b. DICER1 and hypoxia were also found to be negatively 
correlated in a large clinical series of breast cancer gene expression 
studies and both low DICER expression and high hypoxia were 
associated with poor outcome. Collectively, these data indicate that 
hypoxic suppression of DICER leads to increased stemness through 
repression of the mIR200 family and suggest this effect may 
contribute to the known association of hypoxia with metastasis and 
poor outcome in patients.  
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There is no doubt that the story of Medical Physics has been a story of 
incredible success. Academic and professional contributions that 
Medical Physics has made in the areas of radiation therapy and 
imaging are too many to list. The academic advances have been 
successfully translated to the clinics, leading to wide recognition of 
Medical Physics as an essential health profession. This success has lead 
to maturation of the field, reflected in strong consolidation of the 
professional part of Medical Physics. Particularly in the US, this 
consolidation has been accelerated with the recently implemented 
strict CAMPEP (Commission on Accreditation of Medical Physics 
Educational Programs) requirements that have tightened education 
and training requirements for Medical Physics professionals, leaving 
little room for academic freedom and expansion of the field. This 
consolidation exposed challenges in front of the academic part of 
Medical Physics. 
Concerned about the long-term future of Medical Physics as an 
academic and professional discipline, the American Association of 
Physicists in Medicine (AAPM) has established a Working Group on the 
Future of Medical Physics Research and Academic Training (WG 
FUTURE) with a charge “to initiate, coordinate and lead activities to 
secure sustainable growth and improvement in the long-term future 
environment for high quality research and academic training of 
physicists in medicine”. WG FUTURE has already had a significant 
impact through development of the AAPM Research Strategic Plan, 
organization of a series of “Expanding Horizons” workshops and 
initiation of many other activities.  
In this talk, the activities of WG FUTURE will be outlined, particularly 
activities of high interest to the ESTRO members. In additional, 
potential synergistic activities will be proposed to further strengthen 
global collaboration of medical physicists and secure long-term future 
of the field. 
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In the question how the physicist retains responsibility for the patient, 
is related to the legal as well as ethical considerations. In this paper 
we will provide an overview of the legal implications in different 
countries of the ESTRO membership as well as the US. 
On an ethical level there is a need to decide to what level the 
physicist carries responsibility. It is clear however that the physicist is 
definitely responsible in providing the tools to the physician and to 
make sure these tools provide the advertised accuracy and quality 
control for these tools needs to be available.  
On the other hand when the patient is being treated it is still the 
physicians' responsibility to decide which treatment (if any) will be 
most beneficial to the patient.  
The question then remains: "which is the physicist's responsibility?" 
By using specific examples from errors and use cases we will 
investigate the different possibilities. Finally, a town hall round of 
questions is started to start discussions.  
   
SP-0648   
Future developments of medical physics inside and outside 
radiotherapy  
D.R. Olsen 
Faculty of Mathematics and Natural Sciences, University of Bergen, 
Norway 
 
Abstract not received 
 
